

Stuart J Peacock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6340367/publications.pdf>

Version: 2024-02-01

171
papers

5,086
citations

109321

35
h-index

118850

62
g-index

176
all docs

176
docs citations

176
times ranked

6768
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. <i>Clinical Oncology</i> , 2022, 34, e7-e17.	1.4	7
2	Effect of Early Palliative Care on End-of-Life Health Care Costs: A Population-Based, Propensity Score–Matched Cohort Study. <i>JCO Oncology Practice</i> , 2022, 18, e183-e192.	2.9	25
3	Impact of TAILORx on chemotherapy prescribing and 21–gene recurrence score–guided treatment costs in a population–based cohort of patients with breast cancer. <i>Cancer</i> , 2022, 128, 665-674.	4.1	8
4	Feasibility, Acceptability, and Clinical Significance of a Dyadic, Web-Based, Psychosocial and Physical Activity Self-Management Program (TEMPO) Tailored to the Needs of Men with Prostate Cancer and Their Caregivers: A Multi-Center Randomized Pilot Trial. <i>Current Oncology</i> , 2022, 29, 785-804.	2.2	6
5	Vaccine nationalism will persist: global public goods need effective engagement of global citizens. <i>Globalization and Health</i> , 2022, 18, 14.	4.9	7
6	Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group. <i>Current Oncology</i> , 2022, 29, 2046-2063.	2.2	2
7	Diverse Discussion in Public Deliberation on Cancer Drug Funding. <i>Journal of Deliberative Democracy</i> , 2022, 18, .	0.6	0
8	Human papillomavirus–based screening at extended intervals missed fewer cervical precancers than cytology in the <sc>HPV For Cervical</sc> Cancer (<sc>HPV FOCAL</sc>) trial. <i>International Journal of Cancer</i> , 2022, 151, 897-905.	5.1	5
9	Risk of Anxiety and Depression after Diagnosis of Young-Onset Colorectal Cancer: A Population-Based Cohort Study. <i>Current Oncology</i> , 2022, 29, 3072-3081.	2.2	4
10	“Bring the Hoses to Where the Fire Is”: Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare Costs. <i>Value in Health</i> , 2022, 25, 1307-1316.	0.3	4
11	Willingness to Self-Collect a Sample for HPV-Based Cervical Cancer Screening in a Well-Screened Cohort: HPV FOCAL Survey Results. <i>Current Oncology</i> , 2022, 29, 3860-3869.	2.2	3
12	The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	2.4	2
13	Cancer Patients’s Experiences with Telehealth before and during the COVID-19 Pandemic in British Columbia. <i>Current Oncology</i> , 2022, 29, 4199-4211.	2.2	5
14	Trajectory of psychosocial symptoms among home care patients with cancer at end-of-life. <i>Psycho-Oncology</i> , 2021, 30, 103-110.	2.3	14
15	Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 22-29.	2.5	14
16	Understanding cancer survivors’s reasons to medicate with cannabis: A qualitative study based on the theory of planned behavior. <i>Cancer Medicine</i> , 2021, 10, 396-404.	2.8	18
17	Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110210.	0.9	10
18	Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review. <i>Pharmacoeconomics</i> , 2021, 39, 373-377.	3.3	6

#	ARTICLE	IF	CITATIONS
19	End-of-life outcomes with or without early palliative care: a propensity score matched, population-based cancer cohort study. <i>BMJ Open</i> , 2021, 11, e041432.	1.9	15
20	Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland. <i>Health Policy</i> , 2021, 125, 307-319.	3.0	7
21	A study protocol for a multicenter randomized pilot trial of a dyadic, tailored, web-based, psychosocial, and physical activity self-management program (TEMPO) for men with prostate cancer and their caregivers. <i>Pilot and Feasibility Studies</i> , 2021, 7, 78.	1.2	3
22	Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home Care. <i>Current Oncology</i> , 2021, 28, 1641-1651.	2.2	11
23	Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial. <i>Cancer Medicine</i> , 2021, 10, 2996-3003.	2.8	9
24	Cervical screening during the COVID-19 pandemic: optimising recovery strategies. <i>Lancet Public Health</i> , The, 2021, 6, e522-e527.	10.0	37
25	Sociodemographic characteristics of women with invasive cervical cancer in British Columbia, 2004-2013: a descriptive study. <i>CMAJ Open</i> , 2021, 9, E424-E432.	2.4	4
26	Canadian Colorectal Cancer Screening Guidelines: Do They Need an Update Given Changing Incidence and Global Practice Patterns?. <i>Current Oncology</i> , 2021, 28, 1558-1570.	2.2	11
27	Addressing prioritization in healthcare amidst a global pandemic. <i>Healthcare Management Forum</i> , 2021, 34, 252-255.	1.4	8
28	The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. <i>Value in Health</i> , 2021, 24, 862-873.	0.3	14
29	Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada. <i>Current Oncology</i> , 2021, 28, 2708-2719.	2.2	7
30	Impact of a cancer diagnosis on the income of adult cancer survivors: a scoping review protocol. <i>BMJ Open</i> , 2021, 11, e047315.	1.9	2
31	Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials. <i>Journal of Cancer Policy</i> , 2021, 30, 100304.	1.4	4
32	Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions. <i>Journal of Cancer Policy</i> , 2021, 30, 100303.	1.4	4
33	Women's acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results. <i>BMJ Open</i> , 2021, 11, e052084.	1.9	6
34	42: Understanding End-of-Life Cancer Care in Canada: an Updated 12-Year Retrospective Analysis of Three Provinces' Administrative Health Care Data. <i>Radiotherapy and Oncology</i> , 2021, 163, S20-S21.	0.6	0
35	Quality of End-of-Life Cancer Care in Canada: A 12-Year Retrospective Analysis of Three Provinces' Administrative Health Care Data Evaluating Changes over Time. <i>Current Oncology</i> , 2021, 28, 4673-4685.	2.2	6
36	Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per protocol eligible for routine screening. <i>International Journal of Cancer</i> , 2020, 146, 1810-1818.	5.1	0

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review. <i>Cancer</i> , 2020, 126, 148-155.	4.1	16
38	Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , 2020, 126, 1530-1540.	4.1	13
39	Acceptability and Usefulness of a Dyadic, Tailored, Web-Based, Psychosocial and Physical Activity Self-Management Program (TEMPO): A Qualitative Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3284.	2.4	11
40	Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada. <i>EJHaem</i> , 2020, 1, 69-78.	1.0	1
41	Comparing Childhood Cancer Care Costs in Two Canadian Provinces. <i>Healthcare Policy</i> , 2020, 15, 76-88.	0.6	2
42	Modes of coordination for health technology adoption: Health Technology Assessment agencies and Group Procurement Organizations in a polycentric regulatory regime. <i>Social Science and Medicine</i> , 2020, 265, 113528.	3.8	4
43	The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30. <i>MDM Policy and Practice</i> , 2019, 4, 238146831984253.	0.9	16
44	Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs. <i>BMC Public Health</i> , 2019, 19, 977.	2.9	11
45	Evidence, values, and funding decisions in Canadian cancer systems. <i>Healthcare Management Forum</i> , 2019, 32, 293-298.	1.4	7
46	Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. <i>BMJ Open</i> , 2019, 9, e024719.	1.9	32
47	Real-World Costing Analysis for Diffuse Large B-Cell Lymphoma in British Columbia. <i>Current Oncology</i> , 2019, 26, 108-113.	2.2	8
48	Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 573-576.	2.1	19
49	Special Supplement on Canadian Cancer Costing Research. <i>Current Oncology</i> , 2019, 26, 85-86.	2.2	0
50	Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy. <i>Health Research Policy and Systems</i> , 2019, 17, 17.	2.8	18
51	How Procurement Judges The Value of Medical Technologies: A Review of Healthcare Tenders. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 50-55.	0.5	26
52	Communicating uncertainty in cancer prognosis: A review of web-based prognostic tools. <i>Patient Education and Counseling</i> , 2019, 102, 842-849.	2.2	11
53	Conducting clinical trials' costs, impacts, and the value of clinical trials networks: A scoping review. <i>Clinical Trials</i> , 2019, 16, 183-193.	1.6	42
54	Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. <i>Pharmacoeconomics</i> , 2018, 36, 225-238.	3.3	77

#	ARTICLE	IF	CITATIONS
55	The economic burden of cancer care in Canada: a population-based cost study. CMAJ Open, 2018, 6, E1-E10.	2.4	79
56	Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013. Cancer, 2018, 124, 1269-1278.	4.1	20
57	Benefits of Early Palliative Care in the Community: A Propensity Score Matched Cancer Cohort. Journal of Pain and Symptom Management, 2018, 56, e42.	1.2	0
58	Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. Obstetrical and Gynecological Survey, 2018, 73, 632-634.	0.4	2
59	Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1340-1351.	4.9	30
60	Pan-Canadian Quality Indicators for Patients at End of Life Derived from interRAI Data. Journal of Pain and Symptom Management, 2018, 56, e59-e60.	1.2	1
61	Long-term effects of cancer on earnings of childhood, adolescent and young adult cancer survivors – a population-based study from British Columbia, Canada. BMC Health Services Research, 2018, 18, 826.	2.2	16
62	Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysis. CMAJ Open, 2018, 6, E292-E299.	2.4	4
63	Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months. JAMA - Journal of the American Medical Association, 2018, 320, 43.	7.4	190
64	Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada. BMC Health Services Research, 2018, 18, 339.	2.2	16
65	Understanding Contextual Factors in Cost, Quality and Priority Setting Decisions in Health Comment on "Contextual Factors Influencing Cost and Quality Decisions in Health and Care: A Structured Evidence Review and Narrative Synthesis". International Journal of Health Policy and Management, 2018, 7, 1145-1147.	0.9	3
66	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. Journal of Thoracic Oncology, 2017, 12, 1210-1222.	1.1	112
67	Theoretical Foundations of MCDA. , 2017, , 9-28.		8
68	Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 1523-1531.	10.7	158
69	COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008. International Journal of Technology Assessment in Health Care, 2017, 33, 481-486.	0.5	4
70	The Girls-Only HPV Vaccination Program in British Columbia, Canada: A Qualitative Study Exploring Expert Informants' Perspectives of Input From the Public. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 726-727.	0.7	0
71	HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. International Journal of Cancer, 2017, 140, 440-448.	5.1	70
72	Economic Evaluation in Adolescent and Young Adult Cancer: Methodological Considerations and the State of the Science. Pediatric Oncology, 2017, , 779-799.	0.5	2

#	ARTICLE	IF	CITATIONS
73	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. <i>Healthcare Policy</i> , 2017, 12, 95-108.	0.6	12
74	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. <i>Healthcare Policy</i> , 2017, 12, 95-108.	0.6	19
75	A Time-and-Motion Approach to Micro-Costing of High-Throughput Genomic Assays. <i>Current Oncology</i> , 2016, 23, 304-313.	2.2	11
76	Cost and Resource Utilization in Cervical Cancer Management: A Real-World Retrospective Cost Analysis. <i>Current Oncology</i> , 2016, 23, 14-22.	2.2	7
77	Temporal Association between Home Nursing and Hospital Costs at End of Life in Three Provinces. <i>Current Oncology</i> , 2016, 23, 42-51.	2.2	11
78	Population-Based Trends in Systemic Therapy Use and Cost for Cancer Patients in the Last Year of Life. <i>Current Oncology</i> , 2016, 23, 32-41.	2.2	19
79	Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada. <i>Oncologist</i> , 2016, 21, 1099-1106.	3.7	17
80	Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 535-544.	2.5	23
81	Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 526-535.	2.5	10
82	Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada. <i>BMC Health Services Research</i> , 2016, 16, 206.	2.2	10
83	Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. <i>British Journal of Cancer</i> , 2016, 115, 1487-1494.	6.4	10
84	Phase-specific and lifetime costs of cancer care in Ontario, Canada. <i>BMC Cancer</i> , 2016, 16, 809.	2.6	71
85	High performance in healthcare priority setting and resource allocation: A literature- and case study-based framework in the Canadian context. <i>Social Science and Medicine</i> , 2016, 162, 185-192.	3.8	23
86	Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format. <i>Quality of Life Research</i> , 2016, 25, 637-649.	3.1	58
87	Multiple Criteria Decision Analysis for Health Care Decision Making – An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016, 19, 1-13.	0.3	437
88	Comparative Effectiveness Research and Priority Setting. , 2016, , 95-103.		2
89	Multiple Criteria Decision Analysis for Health Care Decision Making – Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016, 19, 125-137.	0.3	320
90	Health Utility during the First Two Years of Treatment of Hematological Malignancies. <i>Blood</i> , 2016, 128, 3608-3608.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Public attitudes and values in priority setting. <i>Israel Journal of Health Policy Research</i> , 2015, 4, 29.	2.6	8
92	“Real-world” health care priority setting using explicit decision criteria: a systematic review of the literature. <i>BMC Health Services Research</i> , 2015, 15, 164.	2.2	58
93	Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2015, 37, 412-420.	0.7	11
94	Plasma pro-surfactant protein B and lung function decline in smokers. <i>European Respiratory Journal</i> , 2015, 45, 1037-1045.	6.7	30
95	A Time-Trend Economic Analysis of Cancer Drug Trials. <i>Oncologist</i> , 2015, 20, 729-736.	3.7	35
96	Cost-effectiveness of therapies for melanoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 229-242.	1.4	9
97	Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment. <i>Cmaj</i> , 2015, 187, E190-E197.	2.0	76
98	Comparative Effectiveness Research and Priority Setting. , 2015, , 1-9.		0
99	Cost-effectiveness of population-based mammography screening strategies by age range and frequency. <i>Journal of Cancer Policy</i> , 2014, 2, 97-102.	1.4	8
100	Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density. <i>Journal of Medical Screening</i> , 2014, 21, 180-188.	2.3	17
101	Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control. <i>Social Science and Medicine</i> , 2014, 122, 130-139.	3.8	20
102	Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. <i>International Journal of Cancer</i> , 2014, 135, 939-947.	5.1	39
103	HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 179-187.	0.5	30
104	Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1449-1458.	1.1	45
105	Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. <i>BMC Cancer</i> , 2014, 14, 586.	2.6	41
106	The Cost-Effectiveness of Clinical Genomic Tests to Aid CR1 Treatment Decisions in Intermediate-Risk AML. <i>Blood</i> , 2014, 124, 2650-2650.	1.4	0
107	Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers. <i>BMC Cancer</i> , 2013, 13, 339.	2.6	47
108	Decision maker perceptions of resource allocation processes in Canadian health care organizations: a national survey. <i>BMC Health Services Research</i> , 2013, 13, 247.	2.2	20

#	ARTICLE	IF	CITATIONS
109	Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 203.	2.4	40
110	Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). <i>BMC Health Services Research</i> , 2013, 13, 454.	2.2	28
111	A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score [®] assay in oestrogen receptor positive node negative breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 2469-2475.	2.8	50
112	Commentary on: Quality-of-Life Effects of Prostate-Specific Antigen Screening. <i>Urology</i> , 2013, 81, 7-8.	1.0	2
113	Health care costs associated with hepatocellular carcinoma: A population-based study. <i>Hepatology</i> , 2013, 58, 1375-1384.	7.3	64
114	Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013, 1, E1-E8.	2.4	85
115	Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013, 1, E151-E158.	2.4	37
116	Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 753-765.	1.4	24
117	Exploring Colposcopists' Attitudes Towards Use of HPV Testing as a Primary Screening Tool for Cervical Cancer in British Columbia. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 657-663.	0.7	3
118	Priority setting methods and cancer control. , 2013, , .		0
119	Utility Weights for the Vision-related Assessment of Quality of Life (AQoL)-7D Instrument. <i>Ophthalmic Epidemiology</i> , 2012, 19, 172-182.	1.7	17
120	Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial â€” the HPV FOCAL Study. <i>British Journal of Cancer</i> , 2012, 107, 1917-1924.	6.4	71
121	Costâ€”effectiveness of rituximab in follicular lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 569-577.	1.4	10
122	Assessing the Realâ€”World Costâ€”Effectiveness of Adjuvant Trastuzumab in HERâ€”2/neu Positive Breast Cancer. <i>Oncologist</i> , 2012, 17, 164-171.	3.7	44
123	Using evaluation theory in priority setting and resource allocation. <i>Journal of Health Organization and Management</i> , 2012, 26, 655-671.	1.3	12
124	Social welfare and the Affordable Care Act: Is it ever optimal to set aside comparative cost?. <i>Social Science and Medicine</i> , 2012, 75, 1156-1162.	3.8	8
125	Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada. <i>European Journal of Cancer</i> , 2012, 48, 1969-1976.	2.8	18
126	Construction of the descriptive system for the assessment of quality of life AQoL-6D utility instrument. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 38.	2.4	124

#	ARTICLE	IF	CITATIONS
127	Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. <i>Value in Health</i> , 2012, 15, 580-585.	0.3	14
128	Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis. <i>Lung Cancer</i> , 2012, 76, 472-477.	2.0	23
129	Improving the Quality of Abstract Reporting for Economic Analyses in Oncology. <i>Current Oncology</i> , 2012, 19, 428-435.	2.2	3
130	Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990-2009. <i>PLoS ONE</i> , 2012, 7, e40917.	2.5	36
131	Design and implementation of a survey of senior Canadian healthcare decision-makers: Organization-wide resource allocation processes. <i>Health</i> , 2012, 04, 1007-1014.	0.3	1
132	Access to Cancer Drugs in Canada: Looking Beyond Coverage Decisions. <i>Healthcare Policy</i> , 2011, 6, 27-35.	0.6	20
133	Integrating public input into healthcare priority-setting decisions. <i>Evidence and Policy</i> , 2011, 7, 327-343.	1.0	18
134	Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis. <i>Journal of Thoracic Oncology</i> , 2011, 6, 2097-2103.	1.1	25
135	Moral Distress Among Health System Managers: Exploratory Research in Two British Columbia Health Authorities. <i>Health Care Analysis</i> , 2011, 19, 107-121.	2.2	44
136	Severity as an independent determinant of the social value of a health service. <i>European Journal of Health Economics</i> , 2011, 12, 163-174.	2.8	16
137	The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 106.	2.4	48
138	A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). <i>BMC Cancer</i> , 2010, 10, 111.	2.6	68
139	Childhood, adolescent, and young adult cancer survivors research program of British Columbia: Objectives, study design, and cohort characteristics. <i>Pediatric Blood and Cancer</i> , 2010, 55, 324-330.	1.5	36
140	Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada. <i>Value in Health</i> , 2010, 13, 703-711.	0.3	25
141	Moral Distress among Healthcare Managers: Conditions, Consequences and Potential Responses. <i>Healthcare Policy</i> , 2010, 6, 99-112.	0.6	20
142	Priority setting in healthcare: towards guidelines for the program budgeting and marginal analysis framework. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 539-552.	1.4	30
143	Moral Distress among Healthcare Managers: Conditions, Consequences and Potential Responses. <i>Healthcare Policy</i> , 2010, 6, 99-112.	0.6	15
144	Identifying research priorities for health care priority setting: a collaborative effort between managers and researchers. <i>BMC Health Services Research</i> , 2009, 9, 165.	2.2	36

#	ARTICLE	IF	CITATIONS
145	How to Control the Costs of Health Care Services – An Inventory of Strategic Options. Healthcare Management Forum, 2009, 22, 23-30.	1.4	3
146	Priority setting in practice: what is the best way to compare costs and benefits?. Health Economics (United Kingdom), 2009, 18, 467-478.	1.7	25
147	Qualitative methodologies in health care priority setting research. Health Economics (United Kingdom), 2009, 18, 467-478.	1.7	21
148	Do quality-adjusted life years take account of lost income? Evidence from an Australian survey. European Journal of Health Economics, 2009, 10, 103-109.	2.8	15
149	Measuring, and identifying predictors of, women's perceptions of three types of breast cancer risk: population risk, absolute risk and comparative risk. British Journal of Cancer, 2009, 100, 583-589.	6.4	11
150	Public participation in health care priority setting: A scoping review. Health Policy, 2009, 91, 219-228.	3.0	283
151	Overcoming barriers to priority setting using interdisciplinary methods. Health Policy, 2009, 92, 124-132.	3.0	75
152	Introducing Priority Setting and Resource Allocation in Home and Community Care Programs. Journal of Health Services Research and Policy, 2008, 13, 41-45.	1.7	23
153	Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). Journal of Oncology Pharmacy Practice, 2008, 14, 105-112.	0.9	12
154	Vision and Quality of Life: Development of Methods for the VisQoL Vision-Related Utility Instrument. Ophthalmic Epidemiology, 2008, 15, 218-223.	1.7	46
155	Priority setting in health care using multi-attribute utility theory and programme budgeting and marginal analysis (PBMA). Social Science and Medicine, 2007, 64, 897-910.	3.8	54
156	Supplier-induced demand: re-examining identification and misspecification in cross-sectional analysis. European Journal of Health Economics, 2007, 8, 267-277.	2.8	22
157	Supplier-Induced Demand. Applied Health Economics and Health Policy, 2006, 5, 87-98.	2.1	37
158	Quality and Cost in Healthcare. Applied Health Economics and Health Policy, 2006, 5, 201-208.	2.1	10
159	A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services. British Journal of Cancer, 2006, 95, 1448-1453.	6.4	16
160	Determinants of Preferences for Genetic Counselling in Jewish Women. Familial Cancer, 2006, 5, 159-167.	1.9	8
161	Using economics to set pragmatic and ethical priorities. BMJ: British Medical Journal, 2006, 332, 482-485.	2.3	84
162	Does an increase in the doctor supply reduce medical fees? An econometric analysis of medical fees across Australia. Applied Economics, 2006, 38, 253-266.	2.2	8

#	ARTICLE	IF	CITATIONS
163	Vision and Quality of Life: The Development of a Utility Measure. , 2005, 46, 4007.		85
164	Strengthening Medicare: will increasing the bulk-billing rate and supply of general practitioners increase access to Medicare-funded general practitioner services and does rurality matter?. Australia and New Zealand Health Policy, 2005, 2, 18.	2.2	11
165	Assessing the capacity of the health services research community in Australia and New Zealand. Australia and New Zealand Health Policy, 2005, 2, 4.	2.2	8
166	Health services research, policy and practice in Australia and New Zealand: a coming of age. Journal of Health Services Research and Policy, 2004, 9, 1-2.	1.7	2
167	Measurement of the Quality of Life for Economic Evaluation and the Assessment of Quality of Life (AQoL) Mark 2 Instrument. Australian Economic Review, 2004, 37, 62-88.	0.7	84
168	Using PBMA in health care priority setting: description, challenges and experience. Applied Health Economics and Health Policy, 2003, 2, 121-7.	2.1	19
169	Strengths and limitations of competitive versus non-competitive models of integrated capitated fundholding. Journal of Health Services Research and Policy, 2002, 7, 56-64.	1.7	13
170	Capitation funding in Australia: imperatives and impediments. Health Care Management Science, 2000, 3, 77-88.	2.6	17
171	A New Formula for Distributing Hospital Funds in England. Interfaces, 1997, 27, 53-70.	1.5	17